Nuveen Asset Management LLC bought a new position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 574,783 shares of the company’s stock, valued at approximately $12,134,000. Nuveen Asset Management LLC owned approximately 1.22% of Amphastar Pharmaceuticals at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in AMPH. Prudential Financial Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 1.4% in the 2nd quarter. Prudential Financial Inc. now owns 63,076 shares of the company’s stock valued at $1,331,000 after acquiring an additional 870 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Amphastar Pharmaceuticals by 15.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock valued at $205,000 after acquiring an additional 1,314 shares in the last quarter. Swiss National Bank grew its holdings in Amphastar Pharmaceuticals by 2.2% during the second quarter. Swiss National Bank now owns 64,400 shares of the company’s stock worth $1,359,000 after purchasing an additional 1,400 shares during the period. Arizona State Retirement System grew its holdings in Amphastar Pharmaceuticals by 2.7% during the second quarter. Arizona State Retirement System now owns 54,756 shares of the company’s stock worth $1,156,000 after purchasing an additional 1,422 shares during the period. Finally, Great West Life Assurance Co. Can grew its holdings in Amphastar Pharmaceuticals by 5.9% during the first quarter. Great West Life Assurance Co. Can now owns 46,463 shares of the company’s stock worth $949,000 after purchasing an additional 2,600 shares during the period. Hedge funds and other institutional investors own 47.27% of the company’s stock.
Amphastar Pharmaceuticals stock opened at $19.77 on Friday. The stock has a 50-day simple moving average of $21.08 and a 200 day simple moving average of $20.79. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.83 and a current ratio of 2.81. The stock has a market capitalization of $928.95 million, a P/E ratio of 45.74 and a beta of 1.14. Amphastar Pharmaceuticals Inc has a 52 week low of $17.71 and a 52 week high of $25.43.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.05. The firm had revenue of $79.00 million during the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the business posted $0.03 earnings per share. Research analysts forecast that Amphastar Pharmaceuticals Inc will post 0.17 earnings per share for the current year.
A number of equities analysts recently commented on the company. BidaskClub cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. ValuEngine cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 20th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Wednesday, July 10th. Finally, TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $24.64.
In other Amphastar Pharmaceuticals news, SVP Yakob Liawatidewi sold 1,515 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $21.24, for a total transaction of $32,178.60. Following the completion of the sale, the senior vice president now directly owns 36,670 shares in the company, valued at $778,870.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $20.78, for a total transaction of $207,800.00. Following the sale, the director now owns 49,309 shares of the company’s stock, valued at $1,024,641.02. The disclosure for this sale can be found here. Insiders have sold 353,979 shares of company stock valued at $7,405,413 over the last 90 days. Company insiders own 30.80% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Read More: Trading Ex-Dividend
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.